News
Marina, ProNAi in cancer deal
BioCentury
March 14, 2012
Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) and Mirna Therapeutics, Inc. Announce License Agreement for Up to $63 Million for the Development
Biospace.com
December 28, 2011
Marina Biotech Reports Significant Developments in Its Ability to Develop Both microRNA Mimetics and Antagonists
Therapeutics Daily
July 8, 2011
Marina Biotech and The Debiopharm Group Partner to Develop and Commercialize RNAi-Based Therapies for the Treatment of Bladder Cancer
Download the PDF
February 3, 2011
Marina Biotech announces interim safety results of long-term toxicology study
Download the PDF
October 26, 2010
Marina Biotech
Bothell, WA
Nasdaq: MRNA
Marina Biotech is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The company is currently employing two proven RNAi platforms to down-regulate the expression of specific proteins that cause disease: TauRNAi and TransKingdom RNAi. These approaches provide the flexibility to optimize oral, systemic and local delivery of RNAi-based therapies to target a wide range of human diseases based on the unique characteristics of the cells and organs involved in each disease.